NASDAQ:HROW

Imprimis Pharmaceuticals Stock Insider Trading

Healthcare > Drug Manufacturers - Specialty & Generic

Buy HROW

*Your capital is at risk

$33.32

+0.460 (+1.40%)

At Close: Jun 03, 2026

Imprimis Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 20.10. In total, the insiders bought 11.77M and sold 2.32M HROW shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	20.10
● Buy	11.77M shares
● Sell	2.32M shares
60% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Mar 04, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 20.1. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 18, 2026 Buy	Common Stock P-Purchase	Silvernail Lauren P Director	Director	1 000 Value: $31.0K
May 18, 2026 Buy	Common Stock P-Purchase	Graves Adrienne L Director	Director	1 000 Value: $31.1K
May 15, 2026 Buy	Restricted Stock Units A-Award	Shojaei Amir Chief Scientific Officer	Officer	10 000 Value: $312.1K
May 14, 2026 Buy	Common Stock P-Purchase	Boll Andrew R. President And CFO	CEO / President	3 500 Value: $104.7K
May 14, 2026 Buy	Common Stock P-Purchase	Baum Mark L Chief Executive Officer	CEO / President	10 000 Value: $302.0K
Mar 04, 2026 Sell	Common Stock, par value $0.001 per share S-Sale	Opaleye Management Inc. 10 Percent Owner	10% Owner	134 000 Value: $5.32M
Mar 04, 2026 Sell	Common Stock, par value $0.001 per share S-Sale	Opaleye Management Inc. 10 Percent Owner	10% Owner	4 263 Value: $169.1K
Mar 03, 2026 Sell	Common Stock, par value $0.001 per share S-Sale	Opaleye Management Inc. 10 Percent Owner	10% Owner	1 309 Value: $51.3K
Mar 03, 2026 Sell	Common Stock, par value $0.001 per share S-Sale	Opaleye Management Inc. 10 Percent Owner	10% Owner	59 000 Value: $2.31M
Feb 27, 2026 Sell	Common Stock, par value $0.001 per share S-Sale	Opaleye Management Inc. 10 Percent Owner	10% Owner	5 000 Value: $270.9K
Jan 30, 2026 Buy	RSU A-Award	Sullivan Patrick William Chief Commercial Officer	Officer	15 000 Value: $614.1K
Jan 30, 2026 Buy	RSU A-Award	Sullivan Patrick William Chief Commercial Officer	Officer	25 000 Value: $1.02M
Jan 30, 2026 Buy	Stock Option (Right to Buy)	Sullivan Patrick William Chief Commercial Officer	Officer	30 000 Value: $1.17M
Jan 06, 2026 Sell	Common Stock, par value $0.001 per share S-Sale	Opaleye Management Inc. 10 Percent Owner	10% Owner	20 000 Value: $1.07M
Dec 12, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Baum Mark L Chief Executive Officer	CEO / President	180 000 Value: $711.0K
Dec 12, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Boll Andrew R. President And CFO	CEO / President	60 000 Value: $237.0K
Dec 12, 2025 Sell	Common Stock F-InKind	Boll Andrew R. President And CFO	CEO / President	26 665 Value: $1.25M
Dec 12, 2025 Buy	Common Stock M-Exempt	Boll Andrew R. President And CFO	CEO / President	60 000 Value: $237.0K
Dec 12, 2025 Buy	Common Stock M-Exempt	Baum Mark L Chief Executive Officer	CEO / President	180 000 Value: $711.0K
Dec 12, 2025 Sell	Common Stock F-InKind	Baum Mark L Chief Executive Officer	CEO / President	79 994 Value: $3.76M
Oct 06, 2025 Buy	Stock Option (Right to Buy)	Mullery Francis William Jr CEO, Imprimisrx	CEO / President	33 000 Value: $1.59M
Oct 06, 2025 Buy	Stock Option (Right to Buy)	Mullery Francis William Jr CEO, Imprimisrx	CEO / President	33 000 Value: $1.59M
Sep 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Pollard Randall E. Chief Accounting Officer	Officer	30 000 Value: $1.17M
Sep 01, 2025 Buy	Common Stock J-Other	Pollard Randall E. Officer	Officer	0 Value: $0
Sep 01, 2025 Buy	Common Stock J-Other	Pollard Randall E. Officer	Officer	0 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT IMPRIMIS PHARMACEUTICALS

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharma...

Read Full Profile Here